Kantoff, Philip W.

Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases

McKay, R., Haider, B., Duh, M. S., Valderrama, A., Nakabayashi, M., Fiorillo, M., Ristovska, L., Wen, L., & Kantoff, P. (2017) · Prostate Cancer and Prostatic Diseases

Bone health and treatmentsManagement of metastatic bone disease

Cited by 49

Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases

Mitchell, J., Camacho, N., Shea, P., Stopsack, K. H., Joseph, V., Burren, O. S., Dhindsa, R. S., Nag, A., Berchuck, J. E., O’Neill, A., et al. (2025) · Nature Communications

BRCA gene mutations in cancerProstate Cancer Treatment and Research

Cited by 19

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.

Petrylak, D. P., Kantoff, P. W., Mega, A. E., Vogelzang, N. J., Stephenson, J., Fleming, M. T., Stambler, N., Petrini, M., Huang, K., & Israel, R. J. (2013) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 19